Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

12.68 -0.84 (-6.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,919
Open 13.72
Bid (Size) 10.58 (1,000)
Ask (Size) 14.30 (400)
Prev. Close 13.52
Today's Range 12.66 - 14.36
52wk Range 2.688 - 15.74
Shares Outstanding 2,676,110
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update
From NextCure
Via GlobeNewswire

Performance

YTD
-4.5%
-4.5%
1 Month
+1.4%
+1.4%
3 Month
+13.8%
+13.8%
6 Month
+135.0%
+135.0%
1 Year
+46.8%
+46.8%

More News

Read More
News headline image
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure (NXTC) Q2 Loss Widens 71% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus ↗
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment ↗
Via Stocktwits
News headline image
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline ↗
Via Stocktwits
News headline image
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
News headline image
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire

Frequently Asked Questions

Is NextCure, Inc. - Common Stock publicly traded?
Yes, NextCure, Inc. - Common Stock is publicly traded.
What exchange does NextCure, Inc. - Common Stock trade on?
NextCure, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NextCure, Inc. - Common Stock?
The ticker symbol for NextCure, Inc. - Common Stock is NXTC on the Nasdaq Stock Market
What is the current price of NextCure, Inc. - Common Stock?
The current price of NextCure, Inc. - Common Stock is 12.68
When was NextCure, Inc. - Common Stock last traded?
The last trade of NextCure, Inc. - Common Stock was at 03/13/26 04:00 PM ET
What is the market capitalization of NextCure, Inc. - Common Stock?
The market capitalization of NextCure, Inc. - Common Stock is 33.93M
How many shares of NextCure, Inc. - Common Stock are outstanding?
NextCure, Inc. - Common Stock has 34M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.